AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008
AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008
The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
Inclusion Criteria:
Exclusion Criteria:
Cd. Autonoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
Campinas, São Paulo 13083-878, Brazil
Santo André, São Paulo 09060-650, Brazil
Edmonton, Alberta T6G 1Z2, Canada
Hangzhou, Zhejiang 310003, China
Tianjin, 300020, China
Bogota, Cundinamarca 110111, Colombia
Shatin, New Territories, Hong Kong
Yekaterinburg, Sverdlovsk Oblast 620102, Russia
Moscow, 125167, Russia
Rostov-on-Don, 344015, Russia
Rostov-on-Don, 344022, Russia
Saint Petersburg, 194291, Russia
Saint Petersburg, 197022, Russia
Saint Petersburg, 197341, Russia
Samara, 443095, Russia
Madrid, 28050, Spain
Bangkok, 10700, Thailand
Gaziantep, Sehit Kamil 27310, Turkey (Türkiye)
Dnipropetrovsk, 49102, Ukraine
Kyiv, 03115, Ukraine
Kyiv, 04112, Ukraine
Nottinhgam, NG5 1PB, United Kingdom